Celadon Pharmaceuticals (LSE:CEL) COGS-to-Revenue : -0.50 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals COGS-to-Revenue?

Celadon Pharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2023 was €-0.04 Mil. Its Revenue for the six months ended in Dec. 2023 was €0.08 Mil.

Celadon Pharmaceuticals's COGS to Revenue for the six months ended in Dec. 2023 was -0.50.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Celadon Pharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 was 150.00%.

Celadon Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Celadon Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals COGS-to-Revenue Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

7.00

3.71

Celadon Pharmaceuticals Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial			7.00	2.08	5.13	4.33	-0.50

Celadon Pharmaceuticals COGS-to-Revenue Calculation

Celadon Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.087
	=	0.00

Celadon Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	-0.039	/	0.078
	=	-0.50

Celadon Pharmaceuticals (LSE:CEL) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Celadon Pharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	-0.039 / 0.078
	=	150.00 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Celadon Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines